Disc Medicine

Thank you for visiting Disc HQ in Watertown, BiotechTV! Brad and CEO John Quisel discuss positive clinical data across all three programs from #EHA2024, including bitopertin for #EPP, DISC-0974 for #anemia of myelofibrosis, and DISC-3405 in healthy volunteers. Full conversation below: https://lnkd.in/eV3_wJ2D

Disc is thrilled to share positive clinical data across our portfolio at #EHA2024, including additional data for bitopertin in #EPP, updated data from our Phase 1b trial of DISC-0974 for MF #anemia, and initial SAD data from our Phase 1 trial of DISC-3405. Join us for our corporate call on Friday, June 14 at 8 am ET. Read more and register here: https://lnkd.in/eQshnEVw

Thank you Healio for chatting with our CMO William Savage, MD, PhD about our DISC-0974 program, initial Phase 1a data, and potential therapeutic benefits for patients with chronic kidney disease (#CKD) and #anemia. We are excited to share more later this year. Read here: https://lnkd.in/ersxXKbn #hematology #hepcidin

Join us this #GlobalPorphyriaDay as we wear #PurpleForPorphyria! Today we join patients and organizations around the world to spread disease awareness and reaffirm our commitment to developing meaningful solutions for the #EPP and #XLP community. #MyPorphyria

Thank you to the Global Porphyria Advocacy Coalition for spotlighting EPP and XLP patients around the world and what it’s like to live in their skin. Learn more about their stories and how you can get involved with Global #Porphyria Awareness Day tomorrow, 5/18. 💜 #MyPorphyria  https://lnkd.in/e_Rh5qWn

Join us and the United Porphyrias Association this Saturday for #GlobalPorphyriaDay as we stand together to raise awareness for these rare diseases and build a brighter future for patients. #Porphyrias are a group of serious, rare genetic disorders that result from altered heme synthesis. Patients with EPP and XLP experience extreme photosensitivity that can lead to excruciating pain reactions. As we continue our mission to improve lives through innovation, we stand with patients, caregivers, and healthcare professionals in the fight against #EPP and #XLP. Check out #MyPorphyria or https://www.porphyria.org/ for resources and symptom information.

We're excited to present at the European Hematology Association (EHA) Annual Congress in Madrid next month! We’ll be sharing updates from our portfolio, including updated data from our Phase 1b study of DISC-0974 in #MF patients with #anemia, preliminary data from our Phase 1 study of DISC-3405, and additional data from our bitopertin trials. Read more: https://lnkd.in/eE6SN8ze #EHA2024

We are proud to partner with the United Porphyrias Association and Shadow Jumpers for Sun Escape Weekend 2024! Today through Sunday, 20 kids with extreme sensitivity to sunlight and their families will embark on an “all fun no sun” adventure. At Disc, we are committed to pursuing the development of treatments that will alleviate suffering and enable patients to lead vibrant lives. We hope every camper has a fun weekend and develops memories that will last a lifetime! https://lnkd.in/dCPtU2vZ

This #RareDiseaseDay, join us in raising awareness for the 300 million people globally living with a rare disease, including those with erythropoietic porphyria (#EPP) and other hematologic disorders.   In alignment with this year’s theme of #ShareYourColors, we had the honor of hosting Craig Leppert, who joined us virtually to share his porphyria story and experience with our whole team. Learn more about the Rare Disease Day events happpening today and how you can help generate change: https://lnkd.in/gk6hbAF

Welcome to Team Disc! We are thrilled to announce the appointment of Pamela Stephenson, MPH to Chief Commercial Officer.   Read more: https://lnkd.in/ecvBMpDv